StemCell Therapy

NEW YORK, NY--(Marketwired - April 26, 2017) - Planda Biotechnology (OTCQB: PLPL) expects Capital Brands, LLC, the developer, marketer, and distributor of both the wildly popular NutriBullet and NutriBullet SuperFoods, to launch its reformulated product, SuperFood Fat Burning Boost, next month. SuperFood Fat Burning Boost is being reformulated to include Planda's Phytofare Catechin Complex. This is a landmark moment for a company like Planda Biotechnology that has just recently moved from solely a research and development company to focusing more on sales and marketing of its Phytofare product.

More than 40 million NutriBullet units have been sold worldwide, it's an Amazon best seller in a number of categories and even Kate Middleton, the Duchess of Cambridge and the wife of Prince William, is a big fan of NutriBullet. Capital Brands produces SuperFood formula mixes that it says is to help "give the consumer the best possible health benefits using only the best and most quality ingredients available." The company focuses on nutrient extraction in order to deliver the most nutrients possible from food and other ingredients to increase the health of people everywhere.

Capital Brands has chosen Planda Biotechnology's Phytofare as one of those quality ingredients it will deliver, and now some time next month Phytofare is expected to be introduced to Capital Brands' retailers (Target, Kohl's, Best Buy, Bed Bath & Beyond, Walmart, JC Penny, etc.) and to shoppers who use their website (nutriliving.com) as the active ingredient in SuperFood Fat Burning Boost. This is a deal that should immediately give Planda credibility. After all, Planda invested many years of hard work into the development of Phytofare, and having a worldwide brand that is well-known for using "only the best and most quality ingredients" in its products, speaks loudly to just how potent Phytofare is.

Capital Brands reformulating one of its SuperFood products to include Planda's Phytofare, should also serve as confirmation for the many years of research and the human clinical trials that Planda conducted to prove that its product is highly bioavailable. Bioavailability is essentially the measure of how much of a drug or supplement is able to be absorbed into the bloodstream and how long it can remain there so that the body can realize its health benefits. In the case of Planda's Phytofare Catechin Complex, Capital Brands obviously feels that the results will offer exactly what its customers want.

A human clinical trial showed Planda's product offers 10 times more bioavailability than the commercially available extract it was compared to, and the results from the clinical trial, which was conducted in South Africa by North West University, have allowed Planda to advertise exactly what consumers are looking for -- a more potent green tea extract.

Green tea's health benefits come from the 8 catechins, a type of antioxidant, found in the leaves of the tea plant. In Planda's clinical trial, all 8 of those catechins were present in the bloodstream versus only two found when participants consumed the commercial extract that was used in the clinical testing. Phytofare also provided 5 times greater absorption of those catechins, and the clinical trial found that the life span of the catechin's molecules in the bloodstream was doubled in Phytofare.

When consumers shop for health products, they're looking for those that have proven themselves in clinical trials, and, in turn, can boast of higher bioavailability. Capital Brands has created a worldwide brand with that thinking in mind, and it's no mistake that the company has landed at Planda's door.

The benefit to those using the Planda's Phytofare Catechin Complex is that with higher bioavailability or absorption rate, the phytonutrients are in the bloodstream in greater quantities and for twice as long, and now as the company has become fully focused on sales and marketing, the credibility of this NutriBullet deal along with powerful clinical trial results, should help the company become extremely competitive in the market.

About Stock Market Media GroupStock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles.

We may from time to time include our own opinions about our featured companies, their businesses, markets and opportunities. Any opinions we may offer are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers and viewers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any company are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: http://www.sec.gov. We also recommend as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications are not a recommendation to buy or sell a security.

Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that SMMG is compensated $5,000 per month by Plandai Biotechnology for content development. Neither SMMG nor anyone associated with it owns shares in PLPL.

For more information: http://www.stockmarketmediagroup.com.

See original here:
Plandai Biotechnology Gains Credibility with NutriBullet Deal - Marketwired (press release)

ProShares UltraShort Nasdaq Biotechnology (BIS) currently has a 14-day Commodity Channel Index (CCI) of -291.59. Despite the name, CCI can be used on other investment tools such as stocks. The CCI was designed to typically stay within the reading of -100 to +100. Traders may use the indicator to determine stock trends or to identify overbought/oversold conditions. A CCI reading above +100 would imply that the stock is overbought, and a reading of -100 would imply that the stock is oversold.

A populartool among technical stock analysts is the moving average. Moving averages are considered to be lagging indicators that simply take the average price of a stock over a certain period of time. They may also be used to assist the trader figure out proper support and resistance levels for the stock. Currently, ProShares UltraShort Nasdaq Biotechnology (BIS) has a 200-day MA of 31.84, and a 50-day of 27.97. Presently, the stock has a 14-day RSI of 40.66, the 7-day is sitting at 31.69, and the 3-day is resting at 18.34. The Relative Strength Index (RSI) is one of multiple popular technical indicators created by J. Welles Wilder. Wilder introduced RSI in his book New Concepts in Technical Trading Systems which was published in 1978. RSI measures the magnitude and velocity of directional price movements. The data is represented graphically by fluctuating between a value of 0 and 100. The indicator is computed by using the average losses and gains of a stock over a certain time period. RSI can be used to help spot overbought or oversold conditions. An RSI reading over 70 would be considered overbought, and a reading under 30 would indicate oversold conditions. A level of 50 would indicate neutral market momentum.

ProShares UltraShort Nasdaq Biotechnology (BIS)s Williams Percent Range or 14 day Williams %R presently is at -94.66. In general, if the reading goes above -20, the stock may be considered to be overbought. Alternately, if the indicator goes under -80, this may show the stock as being oversold. We can also take a look at the Average Directional Index or ADX of the stock. For traders looking to capitalize on trends, the ADX may be an essential technical tool. The ADX is used to measure trend strength. ADX calculations are made based on the moving average price range expansion over a specified amount of time. ADX is charted as a line with values ranging from 0 to 100. The indicator is non-directional meaning that it gauges trend strength whether the stock price is trending higher or lower. The 14-day ADX for ProShares UltraShort Nasdaq Biotechnology (BIS) presently sits at 12.12. In general, and ADX value from 0-25 would represent an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would indicate a very strong trend, and a value of 75-100 would signify an extremely strong trend.

View original post here:
Chart Level Analysis on Shares of ProShares UltraShort Nasdaq Biotechnology (BIS) - Baxter Review

GETTY

Pepe Casaas, a 71-year-old Cuban peasant, gets rid of the discomfort of his arthritis by allowing himself to be stung by a scorpion.

The venom has analgesic and anti-inflammatory properties which reduce his pain.

He keeps up to four scorpions near his house so he can guarantee being able to sting himself when he feels the arthritis returning, which is usually once a month.

Casaas told EFE: "The sting doesn't hurt me a bit. And if they're using it as a treatment for cancer in Cuba, it has to be good.

"About eight years ago, I started with this scorpion stuff. My bones were beginning to hurt me, arthritis, and it helped me to feel comfortable.

GETTY

I couldn't brush my teeth, or comb my hair. I got a scorpion, squeezed it, and it stung me twice, and look: my arm's doing fine.

Pepe Casaas

Casaas arthritis had got so bad it was impacting on his daily life, and so he decided to find his own solution.

He explained: I couldn't brush my teeth, or comb my hair. I got a scorpion, squeezed it, and it stung me twice, and look: my arm's doing fine.

Before that, he had used bee stings as a remedy, having come from a family of beekeepers - but he soon graduated onto the larger animal.

While it might seem an unconventional way to treat the condition, scorpion venom is used as an ingredient in Cuban medication.

Getty

1 of 12

GETTY

It is the main component in Vidatox, a homeopathic medicine prescribed for easing pain and other cancer symptoms.

Around 17,000 bottles are sold over the counter in Cuba and in 15 other countries around the world, and 65,000 people have used it for alleviating cancer pain.

Dr. Fabio Linares told EFE: A very important use of Vidatox, which we want to promote, is that of an analgesic and anti-inflammatory, for use against cancer, given that any osteoarthritic process such as rheumatism can be treated with this medication.

Linares says Casaas feels better after the scorpions sting because of its analgesic effect, and due to the venom stimulating the body's natural curative mechanisms and immune system.

GETTY

In fact, such is Cubas belief in the healing powers of scorpion venom, it started clinical trials in 2006 to test whether it could treat cancer.

So far they have found patients quality of life has significantly improved.

Ways of treating arthritis in the UK, according to Arthritis Research UK, include pain-relief drugs, physical therapies such as physiotherapy, and surgery.

Currently 10 million people in the UK are suffering with arthritis, and despite its associations with the elderly, it affects people of all ages.

Excerpt from:
Arthritis cure: Would you use THIS extreme treatment to ease the pain? - Express.co.uk

Nathan Pensini wants to generate awareness about a little-known condition his daughter has.

Support network: Rachelle and Jim Sanderson, Paul Martin and Alyssa, Nathan, Adrian and Cassie Pensini.

NATHAN Pensini knows better than most the pain which Ironman competitors face when they climb Matthew Flinders Drive.

But he also knows its nothing compared to the pain 17-year-old daughter Alyssa has to deal withevery day.

She was diagnosed with juvenile arthritis at the age of 11 and its whythis yearsIronman Australia will have added meaning for him.

Every time I go out I realise the painthat lasts for 10-12 hours or a few days after Ironmanfor every competitoris the type of pain Alyssa goes through every day, he said.

Thats the main driver for us.

Pensini has a great team of people racing alongside him this year in training partner Paul Martin along with Jim and Rachele Sanderson and brother and sister in law Adrian and Cassie.

One in 1000 Australians has juvenile arthritis who have attendedcamps in the last two years.

One is Camp Footloose, an Arthritis and Osteoporosis NSW initiative, which gives children with juvenile arthritis the chance to have fun and achieve personal success in sport and other outdooractivities at their own pace.

Juvenile arthritisis a serious, persistent medical conditionof childhood.

Its surprising how many people have this condition, he said.

Every time I go out I realise the pain that lasts for 10-12 hours or a few days after Ironman for every competitor is the type of pain Alyssa goes through every day. - Nathan Pensini

We dont know if its genetically linked or whether it is caused by eating a certain type of food.

Pensini and his brother first generated awareness about the condition when they competed in the 2015 Ironman.

He said it gatheredamazing support two years ago and now they want to build on that.

Kids are starting to be diagnosed with it from as early as 18 months old now, he said.

Weve got to get awareness out there soI want to make this as recognised as the Jane McGrath Foundation.

Tohelp the Pensinis raise awareness about the condition, for every $50 donated, people will go into the draw to win a mountain bike.

To donate, visit https://racingforjuvenilearthritis.gofundraise.com.au/ or visit the GoFundraise website.

The rest is here:
Ironman pain nothing compared to juvenile arthritis: Pensini - Camden Haven Courier

Shares of Eli Lilly (LLY) were lower by 2.89% to $81.01 on heavy trading volume Tuesday afternoon, after the drug manufacturing company offered no new details as to when the FDA might approve its rheumatoid arthritis drug baricitinib.

The drug won European approval but U.S. regulators rejected it earlier this month. "The FDA specifically stated that additional clinical data are needed to determine the most appropriate doses and to further characterize safety concerns across treatment arms," the company said in a statement.

Eli Lilly was asked on a conference call if it believed it was likely the drug would be approved this year or next, Reuters reported.

"We can't give an estimate on this year or next until we meet with the FDA," the company responded.

Additionally, the company posted better than expected 2017 first quarter adjusted earnings of 98 cents per share on revenue of $5.23 billion. Revenue was roughly in-line with expectations, while EPS beat by 2 cents per share.

What will move markets this quarter and how should investors position themselves ahead of time? Jim Cramer sat down with four of TheStreet's top columnists recently to get their views. Click here to listen to his latest Trading Strategies roundtable with them and read their advice for stocks, bonds, forex and gold.)

Read the original here:
Eli Lilly Stock Falls on Continued Arthritis Drug Approval Delay - TheStreet.com

By Bill Berkrot

(Reuters) - Eli Lilly and Co on Tuesday provided no new information on how long U.S. regulators might delay approval of its closely watched rheumatoid arthritis drug after its surprise rejection by the Food and Drug Administration this month.

Lilly shares, which have outperformed its rivals this year, fell 3 percent to $80.83 even though the U.S. drugmaker reported a slightly higher-than-expected quarterly profit.

"Maybe people are trying to understand where the near-term upside is going to come from," said Credit Suisse analyst Vamil Divan, adding that investors may be taking profit while waiting for clarity on baricitinib.

Lilly reiterated that it was disappointed and disagreed with the FDA assessment on baricitinib, particularly since the medicine won European approval. It said it hoped in the next 60 days to meet with the agency, which had requested more data.

On a conference call with analysts, Lilly was asked whether it was likely in 2017 or 2018 to satisfy FDA concerns outlined in the letter denying approval.

"We can't give an estimate on this year or next until we meet with the FDA," said Christi Shaw, head of Lilly Bio-Medicines.

The FDA asked for more data on proper dosing and safety information on the medicine developed with Incyte Corp.

Lilly expressed confidence it could attain its minimum goal of 5 percent annual revenue growth even without baricitinib approval this year.

Excluding special items, Lilly said it earned 98 cents per share in the first quarter, topping the analysts' average estimate by 2 cents, according to Thomson Reuters I/B/E/S.

Guggenheim Securities analyst Tony Butler said the results benefited from an animal health acquisition, which "makes the beat look less glamorous."

He did call sales of newer diabetes drug Trulicity "tremendous." If baricitinib was approved, he added, "I don't think the stock would be down."

Trulicity, which competes with Novo Nordisk blockbuster Victoza, brought in $372.9 million in the quarter, well ahead of Wall Street estimates of about $328 million.

Lilly maintained its full-year forecast for earnings of $4.05 to $4.15 per share, excluding items.

Revenue rose 7.5 percent to $5.23 billion, roughly in line with expectations.

Other new products with strong sales included Taltz for psoriasis and cancer drug Cyramza. The company called Cyramza sales for gastric cancer in Japan "phenomenal" but acknowledged competitive challenges from immuno-oncology drugs for lung cancer in the United States.

(Reporting by Bill Berkrot in New York and Ankur Banerjee in Bengaluru; Editing by Lisa Von Ahn)

Read the original here:
Lilly gives no time frame on arthritis drug delay; shares fall - Yahoo Finance

25th Apr 17 | Entertainment News

Singer-turned-TV personality Kelly Osbourne wants to help cure fellow Lyme disease sufferers by making stem cell therapy available for all in the U.S.

Ozzy and Sharon Osbourne's daughter contracted the condition after she was bitten by a tick during a party for the rocker's 56th birthday back in 2004, when her mother had a reindeer sanctuary installed at their Los Angeles home.

However, Kelly wasn't properly diagnosed until 2014, months after suffering a seizure while filming an episode of E!'s Fashion Police show in 2013, when doctors claimed her collapse had been caused by epilepsy.

She did some research into her ailments and discovered she was actually struggling with Lyme disease, and promptly sought out alternative treatment to help her overcome the illness.

"I started to actually do the one thing doctors tell you not to do and that's to go online and look it up...," she explained on U.S. breakfast show Good Morning America, "and all roads pointed to Lyme disease so I found a doctor through my mum.

"I went to Frankfurt, Germany, and I did stem cell (therapy) and I got cured," Kelly claimed.

The 32-year-old is lucky to have been in a position to afford the treatment, which involves the transplant of stem cells to heal those damaged by the disease, and now she is looking to get involved in making the therapy more widely available and affordable to others less fortunate.

"It sickens me that that's not available to everyone and that you have to be considered lucky or privileged to get that sort of treatment," she said. "I want to make sure and I will do anything that I can do to make sure that that treatment is available in this country."

Kelly details her experience with the bacterial infection in her new memoir There Is No F**king Secret: Letters from a Bada** B**ch. She isn't the only celebrity to open up about her struggles with Lyme disease - pop star Avril Lavigne, and veteran model Yolanda Hadid and her runway star kids Bella and Anwar Hadid have also been battling the illness.

WENN Newsdesk 2017

Go here to see the original:
Kelly Osbourne campaigning to make stem cell therapy affordable in ... - TV3.ie

by: Marty Toohey, American-Statesman Staff Updated: Apr 24, 2017 - 9:52 PM

SAN ANTONIO, Tx. - Years of testing remain, but UT Health San Antonio researchers say theyve cured Type 1 diabetes in mice.

In peer-reviewed paper, they say a gene transfer can wake up cells in the pancreas to produce insulin.

>> Read more trending news

Health researchers at the University of Texas think they have found a way to trick the body into curing Type 1 diabetes.

The immune system of a person with diabetes kills off useful beta cells, but the UT researchers say they have found a way to make other cells in the pancreas perform the necessary work. Their approach, announced earlier this month in the academic journalCurrent Pharmaceutical Biotechnology, not only would have implications for Type 1, formerly called juvenile diabetes, but also could help treat the far more common Type 2 variety, also known as adult-onset diabetes.

The researchers have cured mice, which are genetically similar to people but different enough that new rounds of animal testing and millions of dollars more are needed before human trials can begin. The researchers approach is sure to garner skeptics, at least in part because it is a significant departure from the many other attempts at curing diabetes, which typically involve transplanting new cells and/or suppressing the immune systems attempts to kill off useful ones.

By contrast, were taking a cell that is already present in the body its there, and its happy and programming it to secrete insulin, without changing it otherwise, said Ralph DeFronzo, chief of the diabetes research at the UT Health Science Center at San Antonio.

Diabetes is a disease characterized by a persons inability to process carbohydrates, a condition that if untreated can lead to often-catastrophic health consequences: lethargy, diminished eyesight, heart attacks, strokes, blindness and a loss of circulation in the feet that could lead to amputation. The Centers for Disease Control and Preventionestimate that in 2014, about 29 million Americans almost 1 in 10 had diabetes.

The core problem is insulin. Most people naturally secrete that substance when they eat something with carbohydrates, such as bread, potatoes and candy bars. Insulin acts like a concierge that escorts the sugar from the bloodstream into the cells, providing the cells with the energy to function. In most people, the body is continually monitoring blood sugar and producing insulin as needed.

In Type 2 diabetes which makes up 9 out of 10 diabetes cases and is generally associated with older people and weight gain the cells reject the insulin, causing sugar to build up in the bloodstream even as cells are starved for energy. Type 2 is often treated with pills that tell the cells to let in the insulin. But in Type 2 diabetes, the body also often gradually loses the ability to produce insulin, requiring insulin injections.

In Type 1 the type the researchers studied the body has simply stopped producing insulin. This type often manifests in children, though it can sometimes develop in adults as well.

The reason the body stops producing insulin is that it kills off the pancreas beta cells, which produce insulin. People with Type 1 diabetes must get their insulin from injections or ingestion, a cumbersome and often imprecise task. Too little insulin and blood sugar levels stay high for extended periods, potentially damaging the body; too much and blood sugar levels crash, possibly causing a person with diabetes to faint or experience an even worse problems, such as a stroke.

DeFronzos partner, Bruno Doiron, decided to see whether the body could reliably produce insulin without transplanting new cells. He used a gene transfer technique on mice, delivered via a virus, that activated insulin production in cells already in the pancreas for instance, those that produced certain enzymes.

Were not fundamentally changing the cell, DeFronzo said. Were just giving it one additional task.

The mice immune systems did not attack the new insulin-producing cells. Most important, according to the findings: The cells produced the right amount of insulin: not so much that they sent a mouse into a blood sugar free fall, not so little that blood sugar levels stayed high. The mice have shown no sign of diabetes for more than a year, according to the findings.

Quite a bit of work remains before testing will start on people. If they can raise enough money they estimate $5 million to $10 million they can proceed to testing on larger animals, such as pigs, dogs or primates, a next step that would be planned in conjunction with the U.S. Food and Drug Administration.

They hope to start human trials in three years.

DeFronzo and Doiron said they expect skepticism but said much of it will be driven by how unconventional their work is. Doiron added that, although the technique is unconventional in the context of diabetes, using a virus to deliver a gene transfer is an established technique, having been approved dozens of times by the FDA to treat diseases.

We can use the cells the body has naturally, Doiron said. This will simply wake up the cells to produce insulin.

Type 1 and Type 2 diabetes

The work of Bruno Doiron and Ralph DeFronzo focuses on Type 1 diabetes, not Type 2.

Both diseases involve a problem with insulin, the substance that healthy bodies produce to take sugar from the bloodstream into the cells and power the body.

Type 2 is far more common. The main issue is that the cells reject insulin, causing sugar to build up in the bloodstream. The common treatment is a pill that makes the cells accept the insulin (and sugar it carries into the cell). But over time, people with Type 2 diabetes often lose the ability to produce insulin.

With Type 1 diabetes, people simply stop producing insulin. Their bodies kill off the cells in the pancreas that produce it.

Those with Type 1 diabetes must inject or ingest insulin. People with Type 2 often grow increasingly dependent on insulin injections, though Type 2 can sometimes be cured or controlled through diet and exercise.

2017 Cox Media Group.

Read the rest here:
Scientists in Texas closer to diabetes cure with unconventional treatment - icFlorida

A Croydon dad who achieved fame as a bailiff on a TV show has been handed a "death sentence" unless a donor can be found to rescue him from terminal blood cancer.

Delroy Anglin is "Croydon born and bred" and found unexpected fame for his work as a bailiff on Channel 5's Can't Pay? We'll Take It Away!

Now the 56-year-old has been stricken by an aggressive form of leukaemia which ravages the blood and bones of its sufferers.

READ MORE: Charity seeking to save life of Croydon TV star tell well-wishers - 'you can save him'

The dad-of-six was confined to a hospital bed while undergoing punishing chemotherapy.

But the searing treatment can only battle the cancer for so long.

Delroy desperately needs a bone marrow transplant in order to beat the debilitating disease.

It is hard to find a matching donor because of his minority background, and he has suffered for months since first hearing the news of his illness.

"You feel as if someone has pronounced a death sentence," said Delroy, from Croydon Old Town.

READ MORE: This 8-year-old Croydon schoolboy is a musical genius despite being deaf

"Life changed in an instant. When they tell you, you're just hoping someone has made a mistake, but they haven't.

"At the end of the day, unless somebody says differently - I'm terminal."

His condition was first discovered after he requested a check-up because he had been catching more colds than he usually would.

A blood test revealed what was really affecting his usually robust health.

READ MORE: Missing People Choir on Britain's Got Talent: Who is missing Crystal Palace fan Lee Boxell?

AML affects the stem cells in bone marrow, causing a huge amount of white blood cells to be produced. Less than half of patients can be cured of the rare disease, which causes a dangerous reduction in the number of red blood cells in the body.

"I think I was in denial because I felt so fine," said Delroy, who has been forced to quit his on-screen work.

"Life changed straight away, from diagnosis to entering the hospital was a matter of days.

"Your life just changes instantly. Everything is chaotic and it remains like that for while."

Delroy, now a grandfather, is continuing to battle the disease, which developed with shocking speed, alongside his family.

His children have rallied to support him, and although his 82-year-old mum worries, her home cooking gives him strength.

"You don't want to worry your mum," said Delroy, who is now being treated at the Royal Marsden in Sutton.

"She does worry. She comes from a generation where leukaemia was a death sentence.

"But you get the home cooking from her and build up your strength it's funny how it never changes.

"You don't know how your kids are going to react. Some react well, some become aware of their own mortality a bit, and hate going to hospitals.

"But my family have reacted so well, and I think that's because they've seen my reaction. They've been absolutely amazing."

The expert bailiff, filmed alongside colleagues for the popular Channel 5 series, is facing the fight with calm determination.

His treatment has been gruelling, but he hopes there may be hope of victory over AML, although only a transplant will guarantee he beats the cancer which claimed his own brother's life 40 years ago.

He said: "For all intents and purposes I'm a pretty young bloke, you know, this is not supposed to happen. It just seems unreal.

"Chemotherapy is tough. The first time I had it I was in a wheelchair after. I looked in the mirror and didn't even recognise myself, I was so weak and frail.

"The next time I forced myself to take a few steps, and not let it do that to me again. Now I'm feeling positive about it. But it won't go away.

READ MORE: Former Crystal Palace striker talks with inspirational honesty about his battle with depression

"A transplant would be a game changer. It's the only way to get rid of it."

Transplanting fresh stem cells from donated bone marrow can treat the cancer.

But because Delroy is of African Caribbean origin his chances of finding a donor are slimmer because of the low number of donors with African Caribbean heritage on the donor register.

And none of Delroy's five siblings fit the criteria to make the vital donation.

His chances would be improved if more people from his background were on the register to donate bone marrow. Delroy thinks that the support he has received could translate into something positive for other sufferers.

"It's strange, people don't usually like bailiffs," he said.

"But I have had so much support, from everyone including complete strangers.

"I'm Croydon born and bred, I know everyone. And being on telly I still don't know how that happened that gives me an opportunity to raise awareness.

"Hopefully we can encourage more people to become donors, becasuse if I'm honest, even I didn't know anything about this issue."

A campaign has now begun to help find the missing match to save Delroy's life and more donors for future sufferers.

READ MORE: Emotional celebration held in memory of Croydon murder victim Bjorn Brown

The #Match4Delroy appeal is to be led by blood cancer charity the African Caribbean Leukaemia Trust (ACLT) and encourages people to join the donor register.

Delroy's daughter Domenique Anglin said: "He is a fantastic father to my siblings and a wonderful grandfather too.

"I am appealing on his behalf to all Caribbean and African people in the UK and abroad to join the register, in the hope they might be the match that saves his life."

Delroy's sister, Janet Hills, is chair of the Met Black Police Association.

She said: If you love Del on the show as much as I love him as my brother, then please, please, please make that commitment today to join the stem cells register."

To join the Stem Cell Register visit aclt.org

The rest is here:
Croydon dad who stars in Channel 5 show needs transplant to live after 'death sentence' diagnosis - Croydon Advertiser

The star ofCant Pay? Well Take It Away!has revealed he desperately needs a bone marrow transplant after being diagnosed with terminal cancer.

TV bailiff Delroy Anglin has an aggressive form of leukaemia which hes called a death sentenceunless a donor an be found.

The 56-year-old father of five is currently undergoing chemotherapy at the Royal Marsden in Sutton to battle the worst symptoms of the disease but the treatment will only be effective for so long.

Delroy has spoken about the toll that chemo has taken on his body, saying:

Chemotherapy is tough. The first time I had it I was in a wheelchair after. I looked in the mirror and didnt even recognise myself, I was so weak and frail.

The next time I forced myself to take a few steps, and not let it do that to me again. Now Im feeling positive about it. But it wont go away. A transplant would be a game changer. Its the only way to get rid of it.

Unfortunately The Croydon Advertiser have reported that finding a donor will be difficult due to Delroys minority background as there arent manydonors with African Caribbean heritage on the donor register.

Delroys life has changed significantly since the diagnosis and hes been forced to quit his on-screen work for Channels 5s Cant Pay? Well Take It Away!

He said:

You feel as if someone has pronounced a death sentence. Life changed in an instant. When they tell you, youre just hoping someone has made a mistake, but they havent.

At the end of the day, unless somebody says differently Im terminal.

Mr Anglin is suffering from a specific type of leukaemia called Acute myeloid leukaemia (AML) whichaffects the stem cells in bone marrow and causes a huge amount of white blood cells to be produced, reducing the number of red cells in the body.

Only half of patients can be cured of the rare disease but despite the debilitating effects Delroy remains hopeful he can beat it and his family have rallied around him to support him during this difficult time.

In order to help save Delroys life the campaign#Match4Delroy has been launched by blood cancer charity the African Caribbean Leukaemia Trust (ACLT) to encourage people to join the donor register.

Here is the original post:
'Can't Pay? We'll Take It Away' Star Reveals 'Death Sentence' - Unilad - UNILAD

A heart attack occurs when one or more of the coronary arteries feeding oxygen-rich blood to the heart muscle become blocked, cutting off the supply and leading to severe pain, tissue death and possible loss of life. Heart attack victims are left with varying degrees of damage to the muscle, and that damage can lead to complications and impaired function down the road.

A new heart patch, though, aims to reverse a large portion of the damage heart attacks leave behind. Developed by a team led by University of Minnesota biomedical engineers, the patch is made from heart stem cells and has been found to be effective in helping heal scar tissue and regrowing healthy heart muscle.

This is a significant step forward in treating the No. 1 cause of death in the U.S., said Brenda Ogle, an associate professor of biomedical engineering at the University of Minnesota, speaking with universitys news service. We feel that we could scale this up to repair hearts of larger animals and possibly even humans within the next several years.

Created using laser-based 3D printing, the patch is a matrix of human heart stem cells and proteins that fully integrates into the heart. When tested on a mouse heart after a simulated heart attack, the patch helped to speed recovery and function in just four weeks.

While the breakthrough is still in its earliest phases of testing, the team, which includes the University of Wisconsin-Madison, is hoping to scale up the project in the near future. Ogle envisions the rollout of a human-ready version of the patch could happen in as little as four years.

Below is a video of the patch cells beating

Go here to see the original:
How Minnesota researchers are helping to heal broken hearts: BTN LiveBIG - Big Ten Network

In a significant public health victory, Mexico has succeeded in eliminating a disease which is the leading cause of blindness worldwide.

The Pan American Health Organization (PAHO) and the World Health Organization (WHO) announced Monday that Mexico is the first country in the Americas to eliminate trachoma as a public health issue. The disease, caused by a bacteria, affects the eye and repeated infections can lead to scarring and even loss of vision.

It primarily affects young children, and can be spread by personal contact or by flies that that have been in contact with the discharge from the eyes or nose of an infected person.

"This is a historic moment for public health in Mexico and the Americas," said Carissa F. Etienne, Director of the Pan American Health Organization (PAHO), WHO regional office for the Americas. "Eliminating a disease is not achieved every day."

Trachoma primarily affects poor and isolated populations in 41 countries; in the Americas, the disease is still prevalent in Brazil, Guatemala, and Colombia.

Mexico has become the third country, after Oman and Morocco, to receive WHO validation for eliminating the disease.

Related: Measles Has Been Eliminated in the Americas, WHO Says

In Mexico, trachoma affected over 146,000 people. The country ramped up its actions in 2004 with the creation of the Trachoma Prevention and Control Program of the Ministry of Health of Chiapas and the strengthening of the WHO SAFE strategy. The "Trachoma Brigades" focused on cleanliness, antibiotics, environmental improvement and surgery for the advanced stage of the disease.

Related: 'Adis Zika!' Elmo Teaches Kids in Caribbean, Latin America about Zika

The program's slogan was "With water, soap and cleanliness you can prevent trachoma." Teachers at schools would also meet with parents regularly to promote better hygiene.

The international criteria for the elimination of trachoma as a public health problem includes prevalence of less than 5 percent in children aged 1 to 9, and less than one case of trachomatous trichiasis (inverted eyelashes) per 1,000 inhabitants.

Follow NBC News Latino on Facebook, Twitter and Instagram

Read more:
Mexico Eliminates Infectious Disease Which Is Leading Cause of ... - NBCNews.com

Last week, as per a notification issued by the Union Health Ministry, India embraced the World Health Organisations (WHO) definition of blindness, and changed its four-decade old criteria of what blindness should be. In the process, India would drastically bring down the number of people who will be considered blind in the country.

Image used for representational purpose only.

The new definition suggests that a person who is unable to count fingers from a stipulated distance of three metres would be regarded as blind. The earlier definition of blindness, adopted in 1976, had a prerequisite of six metres. With the implementation of the new definition, the number of blind people would reduce from 1.20 crore to 80 lakh, according to the National Blindness survey 2007.

The rationale for the erstwhile definition of blindness was to include economic blindness cases that impede a persons ability to earn wages, while the WHO criteria includes people who have social blindness, which hampers the day to day interactions in a persons life.

The definition was revised so that comparable data could be generated so as to analyse it against global estimates and achieve the attain the WHO objective of reducing the prevalence of India to 0.3% of the total population by 2020.

Keeping this move in mind, the name of the government scheme that targets the blind population has been changed from the National Programme for Control of Blindness to the The National Programme for Control of Blindness and Visual Impairment, and its focus would be on both blind as well as visually impaired people.

Deputy Director General of National Programme for Control of Blindness (NPCB), Dr Promila Gupta, stated, Because of the earlier definition, we were projecting a higher figure of blind people from India at any international forum, presenting ourselves in poor light.

It is important to assess this decision of the Union Health Ministry in order to understand how this will impact the blind population legally. India ratified the United Convention on Rights of Persons with Disabilities (CRPD) in 2007. However, the domestic legislation that protects the rights of disabled persons, The Rights of Persons with Disabilities Act, 2016, was only passed in December.

This new legislation would replace The Persons with Disabilities (Equal Opportunities, Protection of Rights and Full Participation) Act, 1995, which would be repealed. The Persons with Disabilities Act was inadequate in recognising the rights enunciated within the CRPD, and did not codify or mention basic CRPD principles of legal capacity and reasonable accommodation.

While the new Act includes a number of new conditions in the disabilities list, it retains blindness as a disability, along with 21 other conditions, and a power to the central government for adding more types of conditions, if required. Low vision is also another condition in this list. The Act casts a responsibility upon appropriate governments to take effective measures to ensure that the persons with disabilities enjoy their fundamental rights equally with others.

The new Act most importantly codifies the principle of reasonable accommodation within the clause that defines discrimination. Section 2 (h) defines discrimination thus discrimination in relation to disability, means any distinction, exclusion, restriction on the basis of disability which is the purpose or effect of impairing or nullifying the recognition, enjoyment or exercise on an equal basis with others of all human rights and fundamental freedoms in the political, economic, social, cultural, civil or any other field and includes all forms of discrimination and denial of reasonable accommodation. It also defines reasonable accommodation as does the CRPD means necessary and appropriate modification and adjustments, without imposing a disproportionate or undue burden in a particular case, to ensure to persons with disabilities the enjoyment or exercise of rights equally with others.

Keeping the new understanding of blindness in India, it is vital to question whether this decision would affect the legal capacity and fundamental freedoms of the 40 lakh population that was regarded as legally blind before this Health Ministry directive, but now have ceased to be so because of a new definition of the disability. How would this affect their employment and capacity to earn a livelihood? And most significantly, how would this affect the way reasonable accommodation is invoked for the blind?

In Pranay Kumar Poddar v. State of Tripura and Others (2017), the Supreme Court asked some very pertinent questions regarding blindness and employment in the medical practice. The bench comprising Justice Dipak Misra and Justice AM Khanwilkar directed the Medical Council of India to constitute a committee of experts to look into the areas of practice that MBBS aspirants with colour blindness could engage in.

The bench also stated that it was an obligation of the Medical Council of India to look into and take progressive measure so that an individual suffering from CVD may not feel like an alien to the concept of equality, which is the fon juris of our Constitution. The amicus curiae, Mr Vishwanathan, argued that since colour blindness was not regarded as a disability under the Persons with Disabilities Act, 1995 or the Rights of Persons with Disabilities Act 2016, there needs to be an examination of the nature and severity of colour blindness and the corresponding subjects they can practice.

The Supreme Court stated: Total exclusion for admission to medical courses without any stipulation in which they really can practice and render assistance would tantamount to regressive thinking. The march of science, apart from our constitutional warrant and values, commands inclusion and not exclusion. That is the way a believer in human rights should think.

In the case of Ashutosh Kumar v. Film and Television Institute of India (2017), the Bombay High Court upheld the rules laid down the Film and Television Institute of India (FTII) that stated that candidates suffering from colour blindness would not be suitable for the course. The Division Bench of Justice Shantanu Kemkar and Justice Prakash Naik rejected the petition of Ashutosh Kumar who was denied admission for a post-graduate course on editing at the Institute.

The court stated that the rules of FTII must be upheld and that the Ashutosh was suffering from colour blindness, and that there was no malafide or arbitrariness in the rules or the recommendations of the expert committee of the Institute. A Delhi High Court case of 2013 adjudicated that colour blindness was not a ground for denying promotion, and directed government authorities to treat CRPF personnel with colour blindness on par with others for promotion.

In Bhagwan Dass and Anr v. Punjab State Electricity Board (2008), the appellant had become completely blind during his service, and the respondent had categorically refused to accommodate him in an alternate position, and instead terminated his service according to the Persons with Disabilities Act.

The Supreme Court, in the case, took a protective view of persons with disabilities and reiterated the judgment in Kunal Singh v. Union of India: In construing a provision of a social beneficial enactment that too dealing with disabled persons intended to give them equal opportunities, protection of rights and full participation, the view that advances the object of the Act and serves its purpose must be preferred to the one which obstructs the object and paralyses the purpose of the Act.

The judgments discussed indicate that there is not a contextual understanding or nuancing of how blindness is perceived in a legal sphere: This means that there is no pattern of adjudicating upon blindness and its relationship with legal rights and the principle reasonable accommodation at the workplace.

With the change in definition of blindness, this nuance is likely to get more difficult and as a result of this, several lakh people may be affected adversely. Changing the definition of blindness, without putting in place proper systems, has created a dangerous situation where blanket discrimination against the visually impaired may take place by both government as well as private actors.

Originally posted here:
India swaps 40-yr-old definition of blindness for WHO criteria: Move may allow blanket discrimination against ... - Firstpost

News & Observer

Uber CEO: Travis Kalanick built Uber into a multibillion-dollar giant ... News & Observer In a quest to build Uber into the world's dominant ride-hailing entity, Travis Kalanick has openly disregarded many rules and norms, backing down only when ... Travis Kalanick Plays the Mythic Role of the Rebel CEO Too WellThe Ringer (blog) Uber chief executive Travis Kalanick plays with fireThe New Daily Uber's CEO Plays With FireNew York Times TechCrunch -The Verge all 193 news articles »

See the article here:
Uber CEO: Travis Kalanick built Uber into a multibillion-dollar giant ... - News & Observer

NIGERIAN TRIBUNE (press release) (blog)

[ April 25, 2017 ] World Earth Day: Stakeholders canvass for adoption of biotechnology for food security Agriculture NIGERIAN TRIBUNE (press release) (blog) The Head of Agriculture Division of the ECOWAS Commission, Ernest Aubee, who spoke with Nigerian Tribune, said the ECOWAS has a biotechnology technology action plan which it is currently implementing across the 15 member states. The Nigerian ...

See more here:
[ April 25, 2017 ] World Earth Day: Stakeholders canvass for adoption of biotechnology for food security Agriculture - NIGERIAN TRIBUNE (press...

LONDON, UNITED KINGDOM--(Marketwired - Apr 24, 2017) - Planda Biotechnology, Inc. (OTCQB: PLPL) ("Planda" or "the Company"), producer of the highly bioavailable Phytofare Catechin Complex, today announced that NutriBullet SuperFood Fat Burning Boost featuring Planda's Phytofare Catechin Complex will be available at retail outlets across the United States as early as May 2017.As announced last November, Capital Brands, the makers of NutriBullet SuperFoods, will now be featuring Planda's Phytofare Catechin Complex as the active ingredient in their product, SuperFood Fat Burning Boost.Capital Brands is expected to launch the revised product containing Phytofare with their retailers and on their website (nutriliving.com) as early as next month.

Callum Cottrell-Duffield, Chief Operating Officer for Planda Biotechnology, commented, "We are excited to have Phytofare associated with such a fantastic brand as Nutribullet. Their use of Phytofare as an active ingredient in their reformulation is a clear indication of their commitment to use only the best ingredients to ensure that their customers receive a supremely effective product. It is also testimony to our shareholders that we are indeed on the right track and that our Phytofare ingredients are game changers for the supplement industry."

NutriBullet has formulated specialized, plant-based SuperFood products using a variety of plant proteins,prebiotic and other dietary fibers, proprietary spice blends, and other unique ingredients etc. that can be easily combined into healthy smoothies using their industry-leading nutrient extraction blenders. The company uses all GMO-free ingredients sourced from the world's most reputable farms that undergo extensive testing for purity, effectiveness and flavor.

Planda operates an 8,000-acre estate in Mpumalanga, South Africa, where it grows and processes the green tea used in its Phytofare products. The company uses solar power for on-site housing and organic, sustainable farming practices to ensure the highest quality. Between the farm and factory, the company provides employment for hundreds of local families and, through profit sharing and rental payments, is able to bring economic value to the Zulu community.

About Capital Brands LLC Capital Brands LLC and its subsidiaries create, produce, and sell NutriBullet blenders as well as SuperFood formula mixes and other accessories for their blenders that help give the consumer the best possible health benefits using only the best and most quality ingredients available. The company focuses on nutrient extraction in order to deliver the most nutrients possible from food and other ingredients to increase the health of people everywhere. For more information, please visit https://www.nutribullet.com/."NutriBullet" and "SuperFood Fat Burning Boost" are the registered trademarks of Capbran Holdings, LLC.

About Planda Biotechnology, Inc. Planda Biotechnology, Inc. and its subsidiaries develop highly phyto-available extracts. Planda Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

See the original post here:
NutriBullets SuperFood Boost Featuring Plandai Biotechnology's ... - Marketwired (press release)

BBNS

Vetr Inc. Downgrades iShares NASDAQ Biotechnology Index (IBB ... The Cerbat Gem iShares NASDAQ Biotechnology Index (NASDAQ:IBB) was downgraded by Vetr from a buy rating to a hold rating in a research note issued to investors on ... iShares NASDAQ Biotechnology Index (IBB) Lifted to Buy at Vetr Inc.Sports Perspectives iShares NASDAQ Biotechnology Index (IBB) Earning Favorable ...BBNS all 4 news articles »

Follow this link:
Vetr Inc. Downgrades iShares NASDAQ Biotechnology Index (IBB ... - The Cerbat Gem

Rheumatoid Arthritis (RA) is a subject near and dear to my heart. Twenty years ago, my daughter who had essentially been sick since she weaned herself from the breast at 10 months old, was chronically ill from that time on. One month wed be in the pediatricians office for an ear infection and the next a sore throat. The overuse of antibiotics by her doctors without any type of sensitivity test to determine what antibiotic would be most effective bordered on malpractice. Eventually nothing worked. At 13, she not only had one of her recurring strept throat infections, this time it turned into an auto-immune disease known as Erythema nodosum (EN). The disease presented with small lumps along her shins about the size of a pea that were bright red and hot. Within a few days these lumps began to grow in diameter and were extremely painful. Medical books described he pain as exquisite. Finally the lumps would take on the appearance of bruises. We were living out of state at the time, and I felt moving home to doctors I knew was warranted. I took her to her regular pediatrician who examined her, left the room to do some research and them came back to give me a diagnosis. Susanna, I think this is Erythema nodosum. It could resolve in a few weeks, a few months, or years. As luck would have it, my daughters case was lengthy, lasting 7 years and leaving her with other health issues including arrhythmias, depression, and juvenile rheumatoid arthritis (JRA).

Many of the allopathic treatments my daughter underwent were worse than the disease itself. Pain killers were addicting, epidural steroid shots caused fainting and back pain which she suffers from to this day, some of the anti-depressants caused the very issue we were trying to cure (Erythema nodosum) as well as suicidal ideation, and overuse of antibiotics completely knocked out her immune system.

Out of desperation I did my own research and discovered Thalidomide, the 1950s and 60s drug used to treat morning sickness in pregnant women was being used in the treatment of Hansens disease also known as leprosy (Erythema nodosum leprosum). I made the intuitive leap that Thalidomide might also work in EN. However, Thalidomide caused severe birth defects. While in the process of securing permission to use the drug, she went into remission.

Finally I met a doctor in Hawaii who told me she used potassium iodide to treat Erythema nodosum and that is was effective 99% of the time. Yet out of the 8-10 specialists we had seen, not one suggested this simple treatment. About that time, my daughter was thought to have breast cancer and had just had a baby so in the confusion, that simple treatment was forgotten.

Although the primary symptoms of the EN stopped once she was in remission, the secondary symptoms of RA, severe pain and inflammation with decreased mobility persisted. When she was 29 I discovered a product called LIMU which contained fucoidan, organic iodine, vitamins, minerals, enzymes, and fatty acids that was a complete nutritional and immune system boost. Within a matter of days she felt better and had improved mobility. Within 6 weeks she was pain free for the first time in almost 17 years. I began to do extensive research on brown seaweed and everything began to make perfect sense. In September my daughter will be 34 and she remains symptom free.

Arthritis is a debilitating auto-immune disease process that strikes about 1% of the population. Causes may include viral, bacterial, or mycoplasma infections so the underlying cause must be alleviated. While there are pharmaceuticals for the treatment of RA, they are not without serious side effects, especially biologics which lower immune function.

I have compiled an extensive list of natural options for Rheumatoid Arthritis. Those marked with an asterisk are what I personally consider most effective.

1. *Water Water is one of the most overlooked nutrients when it comes to health. Some people dont drink enough and some people dont drink water at all. Our bodies are about 60% water so its essential for life, organ function, removal of toxins and joint health. Here also see these home remedies to naturally reduce gout and arthritis pain.

More here:
34 Natural Remedies for Rheumatoid Arthritis, Some of Which Are Based on a Personal Experience - eMaxHealth

A jaguar is recovering from an unique arthritis procedure after a podiatricsurgeon saw the big cat in an Alberta zoo.

Mia a 14-year-old male at the Discovery Wildlife Park near Innisfail is likely the first jaguar to have the procedure, which is usually reserved for humans.

Dr. Karim Ravji, who runs a private orthobiologics clinic in Edmonton, noticed the jaguar's poor health during a visit to the zoo last summer.

"The groundhogs would actually come and taunt it and steal its food and stuff. This beautiful, majestic animal could not leap or pounce and actually was lying there in pain," he told The Calgary Eyeopener.

Ravji talked to zoo owner Doug Bosabout Mia, who has arthritis in his two front knees.

"We were relieving the pain from that with medication, but the medication is just really hard on the animal. It shortens their life span up dramatically. It affects the kidneys and the liver and all that sort of stuff," said Bos.

Ravji consulted with animal experts and found two veterinarians who could help with drawing plasma, spinning off the platelets, and then re-injecting them into Mia's front kneesin hopes of reducing inflammation and promoting tissue regeneration.

Mia the jaguar is sedated and watched over by (from left) STeM MD nurse Heather Pym and Dr. Karim Ravji and Discovery Wildlife Park animal health technicians Tony Stevens and Holli Duffy. (Heather Pym)

"We supplied them with equipment," he said.

Mia was sedated with a blow dart and then given general anesthesia.

"It's not everyday that we have a patient who could wake up and pounce and kill you," said Ravji.

The jaguar was walking again right after the procedure and seems to be doing better, but it takes eight to 12 weeks to see an improvement, Ravji said.

"It's kind of exciting because if it is really effective then it's kind of breaking ground for other zoos and other animals," added Bos.

Zoo staff, thevets and Ravji's medical group all donated their time, and may try and help other animals at the zoo.

"We would do it again," he said. "There's some grizzly bears that have arthritis and Mia's twin, another jaguar, that's got some tendinitis and arthritis issues. This type of injection can be used for tendon, ligament or joint. You just have to have the proper equipment and a good cell collection."

With files from theCalgaryEyeopener

Link:
Arthritic Alberta jaguar treated with cutting-edge human procedure - CBC.ca

The global stem cell therapy market to grow at a CAGR of 36.52% during the period 2017-2021.

The report, Global Stem Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is evolution of new destinations in the development of stem cell therapies. Traditionally, the US and European countries are the key destinations for clinical trials for stem cell therapy products. However, the transformation of regulatory landscape in countries such as Japan and South Korea has made these regions as attractive destinations for the development of stem cell therapy products.

According to the report, one of the major drivers for this market is increase in federal funding in stem cell therapy. Research and clinical trials of stem cell therapy require huge investment, which many research institutes and small companies cannot afford. Therefore, many federal organizations provide funding to these institutes and small companies to help their innovative ideas in the development of stem cell therapies. Worldwide, many government organizations have noticed the importance of regenerative medicine, and thus they have allocated funds and grants in that area. For instance, in the US, the NIH and CIRM provide most of the funds.

Key vendors

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Understanding of stem cell therapy

Part 06: Ethical issues and regulatory landscape

Part 07: Key clinical trials

Part 08: Market landscape

Part 09: Market segmentation by therapy

Part 10: Market segmentation by applications

Part 11: Geographical segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

Part 18: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/gdv8s6/global_stem_cell

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-stem-cell-therapy-market---analysis-technologies-and-forecasts-to-2021---increasing-demand-to-develop-effective-drugs-for-cardiology-and-degenerative-disorders---research-and-markets-300444066.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more:
Global Stem Cell Therapy Market - Analysis, Technologies and ... - PR Newswire (press release)